Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CGON CG Oncology	$25.86 -2.4%	$24.04	$14.80 ▼ $40.47	$1.97B	0.86	837,930 shs	626,383 shs
DNLI Denali Therapeutics	$14.55 -2.5%	$14.15	$10.57 ▼ $33.33	$2.11B	1.32	1.13 million shs	2.00 million shs
GMTX Gemini Therapeutics	$53.71 +1.9%	$45.47	$1.16 ▼ $14.10	$2.33B	-0.12	189,291 shs	705,221 shs
TYRA Tyra Biosciences	$10.43 +1.0%	$9.57	$6.42 ▼ $29.60	$553.73M	1.07	278,865 shs	425,199 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CGON CG Oncology	0.00%	-3.90%	+2.01%	-6.98%	-27.18%
DNLI Denali Therapeutics	0.00%	-1.02%	+2.75%	-3.96%	-32.45%
GMTX Gemini Therapeutics	+1.90%	+7.38%	+17.45%	+5.27%	+38.25%
TYRA Tyra Biosciences	0.00%	-1.14%	+5.78%	-9.30%	-45.48%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CGON CG Oncology	2.4419 of 5 stars	4.5	1.0	0.0	0.0	2.9	0.8	0.0
DNLI Denali Therapeutics	4.3293 of 5 stars	4.5	1.0	0.0	4.7	2.4	2.5	0.0
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	2.0525 of 5 stars	3.5	1.0	0.0	0.0	2.9	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CGON CG Oncology	3.00	Buy	$58.22	125.14% Upside
DNLI Denali Therapeutics	3.06	Buy	$33.71	131.71% Upside
GMTX Gemini Therapeutics	0.00	N/A	N/A	N/A
TYRA Tyra Biosciences	3.00	Buy	$30.83	195.62% Upside

Current Analyst Ratings Breakdown

Latest TYRA, GMTX, DNLI, and CGON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/19/2025	CGON CG Oncology	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$55.00 ➝ $52.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/2/2025	CGON CG Oncology	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$41.00
4/29/2025	CGON CG Oncology	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$66.00 ➝ $68.00
4/28/2025	CGON CG Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$75.00 ➝ $75.00
4/28/2025	CGON CG Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$75.00 ➝ $75.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CGON CG Oncology	$662K	2,977.61	N/A	N/A	($1.94) per share	-13.33
DNLI Denali Therapeutics	$330.53M	6.40	N/A	N/A	$7.42 per share	1.96
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	$2.89 per share	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CGON CG Oncology	-$48.61M	-$1.51	N/A	N/A	N/A	-10,642.98%	-18.97%	-15.36%	8/14/2025 (Estimated)
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/30/2025 (Estimated)
GMTX Gemini Therapeutics	-$71.87M	-$1.00	N/A	N/A	N/A	N/A	-38.78%	-35.88%	N/A
TYRA Tyra Biosciences	-$69.13M	-$1.63	N/A	N/A	N/A	N/A	-24.56%	-23.31%	8/6/2025 (Estimated)

Latest TYRA, GMTX, DNLI, and CGON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/13/2025	Q1 2025	CGON CG Oncology	-$0.36	-$0.45	-$0.09	-$0.45	$0.53 million	$0.05 million
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
3/27/2025	Q4 2024	TYRA Tyra Biosciences	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A
3/25/2025	Q4 2024	CGON CG Oncology	-$0.37	-$0.48	-$0.11	-$0.48	$0.11 million	$0.46 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CGON CG Oncology	N/A	N/A	N/A	N/A	N/A
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
GMTX Gemini Therapeutics	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CGON CG Oncology	N/A	35.32	35.32
DNLI Denali Therapeutics	N/A	9.98	9.98
GMTX Gemini Therapeutics	N/A	71.49	71.49
TYRA Tyra Biosciences	N/A	29.55	29.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CGON CG Oncology	26.56%
DNLI Denali Therapeutics	92.92%
GMTX Gemini Therapeutics	75.42%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
CGON CG Oncology	7.40%
DNLI Denali Therapeutics	12.50%
GMTX Gemini Therapeutics	12.90%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CGON CG Oncology	61	76.23 million	N/A	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
GMTX Gemini Therapeutics	30	43.33 million	37.74 million	Not Optionable
TYRA Tyra Biosciences	20	53.09 million	42.81 million	Optionable

TYRA, GMTX, DNLI, and CGON Headlines

Recent News About These Companies

Tyra Biosciences (NASDAQ:TYRA) Shares Up 7.1% - Time to Buy?

June 10, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up - Time to Buy?

June 9, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives Average Rating of "Buy" from Analysts

June 6, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading Down 6% - Here's What Happened

June 5, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Significant Growth in Short Interest

June 4, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Stake Trimmed by Canaan Partners XI LLC

June 3, 2025 | marketbeat.com

Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 31, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading 6.1% Higher - Here's Why

May 30, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Now Covered by Piper Sandler

May 23, 2025 | marketbeat.com

HC Wainwright Has Optimistic Outlook of TYRA FY2025 Earnings

May 23, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TYRA FY2026 Earnings

May 22, 2025 | marketbeat.com

Vestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 21, 2025 | marketbeat.com

Dimensional Fund Advisors LP Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 19, 2025 | marketbeat.com

Janus Henderson Group PLC Has $24.29 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 18, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 17, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Orbimed Advisors LLC

May 15, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 15, 2025 | marketbeat.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, GMTX, DNLI, and CGON Company Descriptions

CG Oncology NASDAQ:CGON

$25.86 -0.64 (-2.42%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$26.92 +1.06 (+4.11%)

As of 06/13/2025 04:25 PM Eastern

CG Oncology, Inc., an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients. It also develops PIVOT-006, a cretostimogene monotherapy for intermediate-risk NMIBC following transurethral resection of the bladder tumor; and CORE-008 for treating patients with high-risk NMIBC, including BCG-exposed and BCG-naïve NMIBC patients. CG Oncology, Inc. was formerly known as Cold Genesys, Inc. and changed its name to CG Oncology, Inc. in June 2020. The company was founded in 2010 and is based in Irvine, California.

Denali Therapeutics NASDAQ:DNLI

$14.55 -0.38 (-2.55%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$14.56 +0.01 (+0.10%)

As of 06/13/2025 04:43 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Gemini Therapeutics NASDAQ:GMTX

$53.71 +1.00 (+1.90%)

As of 06/13/2025

Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 for treatment of systemic diseases. Gemini Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.

Tyra Biosciences NASDAQ:TYRA

$10.43 +0.10 (+0.97%)

Closing price 06/13/2025 04:00 PM Eastern

Extended Trading

$11.12 +0.69 (+6.61%)

As of 06/13/2025 07:51 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time